The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review
Adrian Alfonso Almodovar Diaz,* Samhar Samer Alouch,* Yogesh Chawla, Wilson I Gonsalves Division of Hematology, Mayo Clinic, Rochester, MN, USA*These authors contributed equally to this workCorrespondence: Wilson I Gonsalves, Division of Hematology, Mayo Clinic, 200 First St...
Saved in:
| Main Authors: | Almodovar Diaz AA, Alouch SS, Chawla Y, Gonsalves WI |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-12-01
|
| Series: | Blood and Lymphatic Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-antibody-drug-conjugate-belantamab-mafodotin-in-the-treatment-of-m-peer-reviewed-fulltext-article-BLCTT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Belantamab Mafodotin Monotherapy for Multiply‐Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland
by: Edmund C. R. Watson, et al.
Published: (2025-06-01) -
Corneal Findings in Patients Treated with Belantamab Mafodotin: A Prospective Case Series Focusing on Corneal Nerves
by: Jakob Schweighofer, et al.
Published: (2025-05-01) -
Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2025-05-01) -
T-Cell Engagers In Multiple Myeloma: A Clinical Review
by: Al-Jarrad A, et al.
Published: (2025-03-01) -
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
by: Pralay Mukhopadhyay, et al.
Published: (2025-02-01)